Efficacy of double dose intradermal vaccination in chronic hepatitis B carriers: A double-blinded randomized clinical trial

Journal of Vaccines and Vaccination

Volumn 3, Issue 4, 2012, Pages

  Mansour Ghanaei, Fariborz ^a   Joukar, Farahnaz ^a   Khalili, Davood ^b   Valeshabad, Ali Kord ^a  

^a GUILAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Hepatitis B virus; Intradermal; Vaccination; Vaccine therapy

Indexed keywords

EID: 84879817528     PISSN: None     EISSN: 21577560     Source Type: Journal    
DOI: 10.4172/2157-7560.1000140     Document Type: Article

References (32)

1. WHO (2000) Hepatitis B.
2. Mahoney FJ (1999) Update on diagnosis, management, and prevention of hepatitis B virus infection. Clin Microbiol Rev 12: 351-366.
3. Lee WM (1997) Hepatitis B infection. N Engl J Med 337: 1733-1745.
4. Gust ID (1996) Epidemiology of hepatitis B infection in the Western Pacific and South East Asia. Gut 38: S18-S23.
5. Lok AS (2002) Chronic hepatitis B. N Engl J Med 346:1682-1683.
6. Farhat A, Khademi G, Mazouman SJ (2003) The prevalence of hepatitis B carrier state in Khorassan province of Iran. Saudi Med J 24: 549-551.
7. Farzadegan H, Shamszad M, Noori-Arya K (1980) Epidemiology of viral hepatitis among Iranian population-a viral marker study. Ann Acad Med Singapore 9: 144-148.
8. Bozergi SH, Ahmadzad Asl M, Ramazani H, Kargarfard H, Alavian SM (2007) Study of viral infections prevalence in blood donors of Qazvin province in different time intervals and during Bam earthquake. Govaresh 11: 242-248.
9. Ghendon Y (1987) Perinatal transmission of hepatitis B virus in high-incidence countries. J Virol Methods 17: 69-79.
10. Margolis HS, Coleman PJ, Brown RE, Mast EE, Sheingold SH, et al. (1995) Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendation. JAMA 274: 1201-1208.
11. Alavian SM, Fallahian F, Lankarani KB (2007) The changing epidemiology of viral hepatitis B in Iran. J Gastrointestin Liver Dis 16: 403-406.
12. Wai CT, Lok AS (2002) Treatment of hepatitis B. J Gastroenterol 37: 771-778.
13. Sprengers D, Janssen HL (2005) Immunomodulatory therapy for chronic hepatitis B virus infection. Fundam Clin Pharmacol 19: 17-26.
14. Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, et al. (1998) Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 102: 968-975.
15. Michel ML, Pol S, Brechot C, Tiollais P (2001) Immunotherapy of chronic hepatitis B by anti HBV vaccine: from present to future. Vaccine 19: 2395-2399.
16. Lebray P, Pichard AV, Michel ML, Fontaine H, Sobeski R, et al. (2003) Immunomodulatory drugs and therapeutic vaccine in chronic hepatitis B infection. J Hepatol 1: S151-S159.
17. Morais EO, Resende MR, Oliveira AM, Sinkoc VM, Garcia MT, et al. (2007) Intradermal hepatitis B vaccination in patients with advanced chronic renal failure: immunogenicity and follow-up. Aliment Pharmacol Ther 25: 849-855.
18. Barraclough KA, Wiggins KJ, Hawley CM, van Eps CL, Mudge DW, et al. (2009) Intradermal versus intramuscular hepatitis B vaccination in hemodialysis patients: a prospective open-label randomized controlled trial in nonresponders to primary vaccination. Am J Kidney Dis 54: 95-103.
19. Chanchairujira T, Chantaphakul N, Thanwandee T, Ong-Ajyooth L (2006) Efficacy of intradermal hepatitis B vaccination compared to intramuscular vaccination in hemodialysis patients. J Med Assoc Thai 2: S33-S40.
20. Playford EG, Hogan PG, Bansal AS, Harrison K, Drummond D, et al. (2002) Intradermal recombinant hepatitis B vaccine for healthcare workers who fail to respond to intramuscular vaccine. Infect Control Hosp Epidemiol 23: 87-90.
21. Larijani B, Zahedi F, Malek-Afzali H (2005) Medical ethics in the Islamic Republic of Iran. East Mediterr Health J 11: 1061-1072.
22. BradenGL (2002) Treatment of hepatitis B. Medscope Education.
23. Lok AS, Chung HT, Liu VW, Ma OC (1993) Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology 105: 1833-1838.
24. Vitiello A, Ishioka G, Grey HM, Rose R, Farness P, et al. (1995) Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest 95: 341-349.
25. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA (1997) DNA vaccines. Annu Rev Immunol 15: 617-648.
26. Charest AF, McDougall J, Goldstein MB (2000) A randomized comparison of intradermal and intramuscular vaccination against hepatitis B virus in incident chronic hemodialysis patients. Am J Kidney Dis 36: 976-982.
27. Laurent PE, Bonnet S, Alchas P, Regolini P, Mikszta JA, et al. (2007) Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. Vaccine 25: 8833-8842.
28. Dikici B, Kalayci AG, Ozgenc F, Bosnak M, Davutoglu M, et al. (2003) Therapeutic vaccination in the immunotolerant phase of children with chronic hepatitis B infection. Pediatr Infect Dis J 22: 345-349.
29. Couillin I, Pol S, Mancini M, Driss F, Brechot C, et al. (1999) Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. J Infect Dis 180: 15-26.
30. Pol S, Nalpas B, Driss F, Michel ML, Tiollais P, et al. (2001) Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J Hepatol 34: 917-921.
31. De Maria N, Idilman R, Colantoni A, Van Thiel DH (2001) Increased effective immunogenicity to high-dose and short-interval hepatitis B virus vaccination in individuals with chronic hepatitis without cirrhosis. J Viral Hepat 8: 372-376.
32. Boni C, Penna A, Ogg GS, Bertoletti A, Pilli M, et al. (2001) Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 33: 963-971.